Incannex Healthcare (IXHL) Issues Q1 Quarterly Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incannex Healthcare Inc. Quarterly Update, Q1 2024
April 16, 2024 8:02 AM EDTMELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (Incannex or the Company), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
Incannex is undertaking various U.S. Food and Drug Administration (FDA) research and development (R&D) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies. The nearest-to-market projects in the Companys therapeutic pipeline are:
IHL-42X drug candidate for Obstructive Sleep Apnea (OSA) - Phase 2/3 studies... More